Company intelligence / Profile preview

Zarbio

Ownership: Private
Development stage: Preclinical

Overview

Zura Bio develops novel monoclonal antibody therapies targeting dual immune pathways to address severe autoimmune and inflammatory conditions. The company has advanced its lead asset tibulizumab into Phase 2 trials for systemic sclerosis and hidradenitis suppurativa. Additional assets include crebankitug and torudokimab, both in early-stage development. Recent financing rounds have supported pipeline advancement.

Therapeutic areas: DermatologyRheumatologyImmunology
Modalities: Monoclonal antibodies (mAbs)Dual-pathway antagonists
Industry: Biotech

Partnerships

In-license agreements with Eli Lilly & Company and Pfizersponsored research agreement with Benaroya Research Institute.

Beyond the preview

Go deeper on Zarbio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zarbio.

Explore the full profile